Received Apr 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
dose leaked out of the syringe and down my arm. Less than 50% went in.; dose leaked out of the syringe and down my arm. Less than 50% went in; Less than 50% went in; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of exposure via skin contact in a 56-year-old patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on an unknown date). On 31-MAR-2025, the patient received the 2nd dose of Shingrix. On 31-MAR-2025, an unknown time after receiving Shingrix, the patient experienced exposure via skin contact (Verbatim: dose leaked out of the syringe and down my arm. Less than 50% went in.), inadvertent exposure to vaccine (Verbatim: dose leaked out of the syringe and down my arm. Less than 50% went in) and underdose (Verbatim: Less than 50% went in). The outcome of the exposure via skin contact, inadvertent exposure to vaccine and underdose were not applicable. Additional Information: GSK receipt Date: 31-MAR-2025 The patient received the second dose of Shingrix, but the dose leaked out of the syringe and down on arm, which led to exposure via skin contact and inadvertent exposure to vaccine products. Less than 50 percent went in, which led to underdose.